DIRECT: results of drug-eluting stent-on-a-wire after 6 months

This balloon expandable stent is combined with a guide 0.014 in its distal part. The platform is made of cobalt chrome and the polymer is bio-degradable. 30 patients were included prospectively and there was angiographic follow-up with IVUS and OCT after 6 months. The reference vessel diameter was 2.69 mm ± 0.48, with a length of 11.72mm ± 3.99.

The success of the device was of 97% and of 100% for the procedure. At the 6 and 12-month follow-up, there were no clinically guided deaths, myocardial infarctions or revascularizations, but there was one revascularization due to angiographic restenosis. 

Conclusion: This new delivery system that integrates the stent and the guide is an attractive alternative for cases where direct stenting is planned.

mark_webster_europcr
Mark Webster
2013-05-22

Original title: Final 6-month results of the DIRECT (Direct-on-a-wire implantation of Rapamicyn-eluting stent with bioabsorbable Carrier Technology) first-in-man study.

More articles by this author

REPRISE II: results obtained with the new valve according to VARC criteria

The objective was to evaluate the safety and efficacy of the Lotus Valve System to treat patients with severe aortic stenosis and high surgical...

DEFLECT I: cerebral protection device in TAVI

Strokes after TAVI occur in between 3.8 and 6.7% of the cases, with new MRI lesions being almost the rule. The TriGuard EDD device...

DISCOVER: new low profile valve with little post-implant regurgitation

The objective of the study was to assess events after 30 days with the DirectFLOW Medical Valve device in patients with severe aortic stenosis...

JUPITER: transapical TAVI device

We evaluated 88 consecutive patients (at this phase) with severe aortic stenosis who received the second-generation device for transapical access. Survival at thirty days...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2026 | ALL-RISE Trial: Coronary Physiological Assessment Using FFRangio

Coronary physiological assessment using pressure-wire techniques (FFR/iFR) carries a Class IA recommendation in ACC/AHA guidelines; however, its use remains limited due to factors such...

ACC 2026 | Protect The Head-To-Head Trial: Randomized Comparison Between Emboliner and Sentinel During TAVI

Ischemic stroke remains one of the most feared complications of TAVI, with a relatively low but persistent incidence of 2–4%, without significant reduction over...

ACC 2026 | PRO-TAVI Trial: Deferring Coronary Angioplasty in Patients Undergoing TAVI

Coronary artery disease is common in patients with severe aortic stenosis undergoing TAVI. Current guidelines recommend considering revascularization in significant coronary lesions, particularly in...